HER2-positive breast cancers are associated with a worse survival, a poorer prognosis, and a higher risk of recurrence than HER2-negative cases; however, they are more sensitive to neoadjuvant trastuzumab-based therapy (12–14). This evidence concerns the gene ERBB2 and breast cancer.